Marijuana’s Potential Rescheduling to Schedule III: What It Means and Why It Matters

Understanding Drug Scheduling Under the Controlled Substances Act

The Controlled Substances Act divides drugs into five schedules based on three primary criteria:

1. Potential for abuse
2. Accepted medical use
3. Likelihood of physical or psychological dependence

Schedule I substances are considered the most dangerous, with no accepted medical use and a high potential for abuse. Schedule III substances are recognized as having medical value and a moderate to low potential for physical dependence.

Examples of Schedule III drugs include ketamine, anabolic steroids, and certain codeine-containing medications.

Marijuana’s placement in Schedule I has long been controversial, particularly as medical marijuana programs have expanded across the majority of U.S. states and as scientific evidence supporting therapeutic uses has grown.

Why Marijuana Is Being Considered for Schedule III Reclassification

On December 18, 2025, President Trump issued an executive order that called upon federal agencies to prioritize and expedite the process toward rescheduling cannabis from a Schedule I drug to a Schedule III. The executive order states that the Attorney General should “take all necessary steps to complete the rulemaking process related to rescheduling marijuana to Schedule III … in the most expeditious manner.”

Agencies such as the Department of Health and Human Services (HHS), the Food and Drug Administration (FDA), and the Drug Enforcement Administration (DEA) are now responsible for completing the formal rulemaking required to reschedule the drug. Ultimately, the final decision must come from the DEA.

Several factors are driving this reconsideration:

• Scientific evidence indicating accepted medical uses for marijuana
• Widespread state-level legalization, particularly for medical use
• Barriers to research created by Schedule I restrictions
• Growing public support for reforming federal cannabis laws

Taken together, these factors have made it increasingly difficult to justify marijuana’s placement in the most restrictive category under federal law.

What Schedule III Status Would and Would Not Change

A move to Schedule III would be significant, but it would also have clear limits.

What Would Change

Federal acknowledgment of medical use
Schedule III status would formally recognize that marijuana has accepted medical applications, aligning federal policy more closely with state medical marijuana programs.

Expanded research opportunities
Researchers would face fewer regulatory hurdles, making it easier for universities and medical institutions to study marijuana’s effects, risks, and therapeutic potential.

Major tax implications for cannabis businesses
Perhaps the most immediate impact would involve IRS Code Section 280E, which currently prevents cannabis businesses from deducting ordinary business expenses. If marijuana is reclassified to Schedule III, many operators could see substantial tax relief.

What Would Not Change

No federal legalization
Marijuana would remain a controlled substance, and non-medical use would still be illegal under federal law.

State laws would still govern legality
States would retain authority over whether marijuana is legal, illegal, or regulated within their borders.

Ongoing federal oversight
The DEA would continue to regulate marijuana, and compliance requirements would remain complex.

Impact on the Cannabis Industry

For licensed cannabis operators, reclassification could be transformative, but not without challenges.

Tax relief alone could significantly improve profitability and cash flow, particularly for small and mid-sized operators that have struggled under 280E. Increased legitimacy may also attract institutional investors who have been wary of federal risk.

Reclassification could also bring stricter FDA involvement in certain cannabis products, more standardized compliance expectations, and increased scrutiny around medical claims and formulations.

Schedule III status could further professionalize the industry, benefiting operators with strong compliance systems while putting pressure on those operating with thinner margins.

Implications for Medical Research and Healthcare

Schedule I status has long been cited as a major barrier to cannabis research. Moving marijuana to Schedule III would ease access to research materials, streamline approval processes, and encourage broader clinical studies.

This could lead to better data on efficacy and risks of using marijuana for therapeutic effects, development of FDA-approved cannabis-derived medications, and clearer guidance for healthcare providers.

For patients, this shift could eventually translate into more standardized dosing, improved safety information, and broader acceptance within mainstream medicine.

How Reclassification Could Affect State Marijuana Laws

Federal rescheduling would not override state marijuana laws, but it could influence them indirectly.

States with existing medical marijuana programs may find it easier to integrate cannabis into traditional healthcare systems. States considering legalization could view federal reclassification as a signal that marijuana policy is moving in a more permissive direction.

At the same time, discrepancies between state and federal law would remain, particularly around interstate commerce and recreational use.

Criticisms, Limitations, and Ongoing Debate

Not everyone views Schedule III reclassification as sufficient.

Many cannabis advocates argue that marijuana should be descheduled entirely and removed from the Controlled Substances Act. Others worry that Schedule III status could benefit pharmaceutical interests more than existing cannabis operators.

Law enforcement and regulatory critics continue to raise concerns about public health, impaired driving, and youth access.

These debates highlight an important reality. Rescheduling is a step forward, but it is not the final word on cannabis reform.

What Happens Next?

While momentum toward Schedule III is real, the process is not yet complete. The DEA must finalize its review, and administrative or legal challenges could affect timing or outcome.

Businesses, investors, healthcare providers, and policymakers are closely watching what happens next, as the decision could reshape the cannabis landscape for years to come.

Conclusion

In summary, the potential reclassification of marijuana to a Schedule III substance represents the most consequential federal cannabis reform in decades. It acknowledges medical value, opens doors for research, and could ease long-standing financial pressures on the cannabis industry.

At the same time, it stops short of full legalization and leaves many structural issues unresolved.

Still, we know that federal cannabis policy is evolving. For anyone with a stake in the future of marijuana, whether medical, commercial, or legal, this moment matters.